Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

189.18 +6.15 (+3.36%)
Streaming Delayed Price Updated: 3:45 PM EDT, Jul 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market... 
Via Finterra
Topics Economy Initial Public Offering
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗
Merck (NYSE: MRK) reportedly ends discussions to acquire Revolution Medicines (NASDAQ: RVMD) after valuation disagreement. 
Via Benzinga
Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗
Via Stocktwits
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Economy Stocks
News headline image
Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗
Stifel expects dip-buyers to step in, saying it would be surprised to see RVMD settle meaningfully below $100, calling the failed talks an “M&A clearing event.” 
Via Stocktwits
News headline image
This Fund Put $3.4 Million Into Navan Despite a 60% Post-IPO Drop ↗
Navan delivers AI-powered travel and expense management software for enterprise clients seeking streamlined operations. 
Via The Motley Fool
Topics Artificial Intelligence Initial Public Offering Regulatory Compliance
News headline image
The Great Mid-Cap Rotation: Fed Rate Cuts Spark a New Bull Run for the 'Forgotten' Middle Market
As the Federal Reserve transitions from its long-standing "higher-for-longer" stance to a deliberate cycle of monetary easing, the U.S. equity market is witnessing a profound shift in leadership. For... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗
When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation. 
Via Stocktwits
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Why Revolution Medicines Stock Surged by 11% Today ↗
The company might become the latest biotech acquisition story soon. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗
Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32... 
Via Benzinga
News headline image
Small-Cap Renaissance: Russell 2000 Scales New Heights While Big Tech Stumbles
In a dramatic shift that has recalibrated the pulse of Wall Street, the Russell 2000 index (RUT) surged to a new record high on January 8, 2026, signaling a definitive breakout for small-cap stocks. As... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Revolution Medicines Stock Soars On Report Of AbbVie Takeover ↗
The Wall Street Journal reported on Wednesday, citing people familiar with the matter, that AbbVie is in advanced talks to buy Revolution Medicines, while adding it couldn’t learn how much AbbVie is... 
Via Stocktwits
News headline image
The Great Rotation: Small Caps Lead the Charge as 2026 Trading Opens
As the opening bells of 2026 ring across Wall Street, a definitive shift in market leadership is unfolding. In the first trading sessions of the new year, the Russell 2000 index, a benchmark for... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? ↗
Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Small-Cap Renaissance: Why 2026 is the Year of the Russell 2000 and XSU
As the sun rises on January 1, 2026, the financial landscape is witnessing a profound shift that many analysts have anticipated for years: the definitive return of the U.S. small-cap sector. After a... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Up Nearly 400% This Year, Can Oklo Stock Still Rise Higher? ↗
Many investors see this nuclear power company as a possible answer to the growing energy needs from artificial intelligence, and it has benefited from that. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Maplebear, Tower Semiconductor, And Eli Lilly Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 10-Nov. 14): Are the Others in Your Portfolio? ↗
Ten large-cap standouts—including Maplebear, Tower Semiconductor, Eli Lilly, On Holding, Albemarle, and key gold/silver miners—rallied last week on strong earnings, upbeat guidance, analyst upgrades,... 
Via Benzinga
News headline image
Revolution Medicines (RVMD) Earnings Transcript ↗
Revolution Medicines (RVMD) Earnings Transcript 
Via The Motley Fool
News headline image
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗
Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers. 
Via Benzinga
News headline image
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing... 
Via Benzinga
Topics Economy
News headline image
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.